21 Serotype Pneumococcal Vaccine Approved for Adults

In COVID-19, Latest News by Precision Vaccinations

Merck announced today that the U.S. Food and Drug Administration (FDA) has approved CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine). 
CAPVAXIVE (V116) is specifically designed to help protect adults against the serotypes that cause most invasive pneumococcal disease (IPD) cases. CAPVAXIVE includes eight unique serotypes not covered by other currently approved pneumococcal vaccines.

Read More